Senators should reject price controls on pharmaceuticals; they will not lower prices and lead to fewer future cures.
The Senate Should Not Implement Price Controls on Pharmaceuticals
Price controls on pharmaceuticals will not lower prices and will lead to fewer future cures.
Limiting Access to Tobacco Harm Reduction Products Harms Public Health
The FDA’s decision to stop Juul from selling e-cigarette products in the U.S. will harm public health.
Regulating PBMs Will Not Lower Drug Costs
Increasing regulations on pharmacy benefit managers will not reduce the cost of pharmaceuticals.
The Convoluted Saga of Maryland’s Purple Line Continues
Since its inception, the Purple Line has been beset by mismanagement, corruption, and delays.
Vaping Saves Lives
Tobacco harm reduction products like e-cigarettes are effective tools that help adults successfully quit smoking.
Unused Cellphones Cost Taxpayers Millions
Mismanagement and a lack of oversight led to the VA wasting taxpayer dollars.
GAO Report Offers Solutions to Duplicative and Overlapping Expenditures
The GAO’s recommendations for 2022 that would add to the $522 billion in savings that have been achieved to date.
California Lawmakers Should Approach Budget Surplus with Caution
The California legislature should focus on providing relief to taxpayers and shoring up the state’s reserves.
California Should Fix Its Broadband Program
California PUC should make sure unserved communities are a priority for the $2 billion broadband grant program created by SB 156.